Compare CRL & WSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | WSE |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Diversified Commercial Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.6B |
| IPO Year | 1999 | 2025 |
| Metric | CRL | WSE |
|---|---|---|
| Price | $293.36 | $11.60 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $198.27 | N/A |
| AVG Volume (30 Days) | 827.6K | ★ 1.4M |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,857,601,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $145.47 | $10.78 |
| 52 Week High | $303.31 | $13.66 |
| Indicator | CRL | WSE |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 40.45 |
| Support Level | $267.27 | $11.22 |
| Resistance Level | $303.31 | $13.23 |
| Average True Range (ATR) | 9.37 | 0.27 |
| MACD | 0.17 | -0.08 |
| Stochastic Oscillator | 86.35 | 28.06 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Wise is a currency conversion platform that matches, where possible, offsetting currency transactions across borders to reduce costs. The group focuses primarily on private clients and small and midsize enterprises, but it is building out its platform business aimed at providing its services as a backend solution to banks. By operating local accounts in each jurisdiction Wise sends money to or receives money from, this fintech offers faster and cheaper currency transfer services than incumbents (banks). Wise has started to broaden its product offering, issuing its clients debit cards and allowing customers to invest funds in various asset management products.